George Ntortas, Partner and Kyriakos Kansos, PartnerWithin this sphere, Fuliginous Management Consulting (FMC) stands as a beacon of expertise and a catalyst for growth, providing unparalleled guidance and solutions that support CDMOs and pharmaceutical companies in taking their businesses to the next level. Going above and beyond, it also offers invaluable support to investors seeking to navigate the complexities of the CDMO market, providing insights into current and future targets and offering a roadmap to achieve challenging yet realistic business objectives.
“We use our industry expertise to create tailored strategies and tools because success is born from precision, not generalities,” says Kyriakos Kansos, partner at Fuliginous Management Consulting.
FMC stands out due to its extensive experience, profound market knowledge, and exposure to diverse business models, particularly within the pharma CDMO sector. This wealth of expertise allows it to craft proposals, innovative solutions, and actionable strategies that refrain from vague generalities and wishful thinking by focusing on practical solutions that deliver tangible results.
The firm’s primary audience comprises top-level management in the contract manufacturing industry, for whom its experts elucidate business potential, illuminate existing shortcomings, outline attainable targets, and set optimal strategic directions. FMC does not stop at guidance; it provides an intricate roadmap detailing the steps required for successful implementation. This roadmap serves as a guide and an essential training material for the execution team, ensuring the path to success is confidently traversed.
Blueprint for Achieving Excellence in CDMO Operations
Rooted deeply in the nuanced aspects of the industry, FMC’s team of seasoned professionals is adept at navigating the complex environment that often perplexes CDMOs. The firm’s professionals provide a comprehensive diagnosis that illuminates the path forward for clients. Through personalised analyses encompassing competition outlook, SWOT assessments, benchmarks against industry best practices, and indepth cost and price evaluations, FMC provides concrete recommendations and customised tools to optimise operations.
Understanding that growth is the lifeblood of any CDMO, FMC embarks on a journey to uncover the growth potential of client businesses. It creates thorough growth plans using revenue and EBITDA projections, analysing business evolution over three to five years, and identifying target segments, customers, and product expansion opportunities. These strategies are not just theoretical constructs; they come with actionable roadmaps, touching on crucial elements like business model enhancements, pricing policies, focused selling tactics, and organisational adjustments. Subsequently, growth becomes a tangible reality.
Regarding pricing, FMC acknowledges that it is pivotal in impacting the success of CDMOs and future sustainability. Employing a systematic approach, it considers product-specific parameters, manufacturing costs, customer preferences, and regional competition to fine-tune pricing strategies.
FMC recognises the need for effectively managing requests for quotations (RFQs) in the CDMO landscape. Here, the firm introduces streamlined RFQ management processes, which simplify complexities and offer a comprehensive view of costs, investments, and business case summaries, enhancing the probability of securing successful RFQs.
The quest for profitable new ventures remains a priority even in stable business environments. In this regard, FMC is a dependable ally, assisting in identifying and managing profitable new business opportunities and fostering organic growth.
Monitoring and reporting constitute critical facets of strategic triumph. FMC’s experts assist in crafting effective monitoring and reporting mechanisms featuring RFQ activity, pipeline value forecasting, profitability improvement impact assessment, and executive dashboards. These tools furnish essential information, aligning organisations with their objectives and promoting informed decision-making.
Enhancing Efficiency in Pharmaceutical Outsourcing
FMC offers pharma companies a novel perspective and multiple services designed to streamline operations, enhance efficiency, and maximise profitability. Its expertise in external manufacturing network optimisation is invaluable for companies with diverse product portfolios. Companies that grow and expand their product offerings work with numerous suppliers, resulting in a scattered portfolio that can hinder relationships and negotiation power. FMC recognises this challenge and conducts extensive research to help them consolidate and optimise their supplier base, ensuring better alignment with strategic goals.
One of FMC’s key offerings is the CDMO evaluation system. It aids clients in establishing an evaluation system that goes beyond the usual parameters, considering factors like customer focus, meeting expectations, strategic alignment, and long-term sustainability. This system categorises suppliers into different groups, helping clients identify preferred partners, those needing improvement, posing high risks, or requiring relocation.
When identifying the right CDMOs, FMC’s prowess shines bright. The firm leverages its vast business network and an extensive European CMO database with detailed technical capabilities to find CDMOs that align with a client’s technological and strategic needs. This process includes sending project briefs to selected CDMOs, confirming their abilities and interests, and providing clients with comprehensive information and recommendations.
FMC also takes the reins of the RFQ management process on behalf of clients. It handles every aspect, from communication package preparation to quotation template creation, CDA signing and negotiation, to ensure a smooth and efficient RFQ process. Clients receive concise offer summaries, supplier descriptions, evaluations, and rankings based on supply and customer-centric criteria and expert recommendations.
Benchmarking is another area where FMC excels, offering pricing benchmarking for outsourced products. It compares product prices to market averages, considering factors such as product technology, supplier type, and manufacturing site location. Clients gain a clear understanding of where their products stand in terms of pricing and profitability potential, allowing them to make informed decisions and profitability improvement plans whenever necessary.
For clients looking to optimise their CDMO portfolio, FMC provides CDMO consolidation services. The firm evaluates its entire portfolio, benchmarks product prices, and develops a detailed consolidation plan that follows a phased approach. It considers contractual obligations and organisational capacity for a seamless transition and implementation of necessary changes.
Finally, FMC offers contract review and negotiation support, utilising its experience with various agreements and a thorough understanding of the CDMO landscape to craft contracts that safeguard client interests and foster fruitful collaborations.
Illuminating the CDMO Path
FMC offers comprehensive mapping services that empower pharmaceutical companies with valuable insights and strategic clarity. Regarding European small molecules CDMOs mapping, the firm identifies CDMOs specialising in producing finished pharmaceutical products capable of manufacturing commercial-scale batches.
Its expansive database encompasses over 320 CMOs/CDMOs with a staggering 651 manufacturing sites worldwide, including 530 strategically located across 36 European countries. This comprehensive database provides insights on manufacturing site numbers, locations, 27 distinct manufacturing technologies, and CDMO development services. Apart from pharmaceuticals, the firm delves into producing food supplements, cosmetics, and veterinary (VET) products, ensuring a holistic understanding of its capabilities.
We use our industry expertise to create tailored strategies and tools because success is born from precision, not generalities
Private Equity’s CDMO Compass
“Research is the key to success, and we have made it a priority to stay ahead of the game. This helps us identify the right CDMO for our customers,” says George Ntortas, partner at Fuliginous Management Consulting.
FMC is a vital partner for private equity investors venturing into pharmaceutical CDMOs. The CDMO industry’s dynamics require specialised insights, and FMC’s expertise in this sector proves vital. It gives investors a comprehensive understanding of their target CDMO’s potential, shedding light on current business projections, growth possibilities, challenges, and associated risks. The firm provides a guideline on realistically capturing future perspectives and helps investors distinguish between ambitious yet achievable exit plans and those that may lead to disappointment, ensuring investments yield the desired results within a sensible timeframe. The firm’s services that support private equity decision-making within the CDMO market are comprehensive. It includes business plan creation or post-acquisition business plan validation, where its experts collaborate with investors to develop challenging yet realistic business plans tailored to the target’s capabilities and potential while considering the CDMO industry’s distinct characteristics. The company identifies cost reduction opportunities—a critical aspect for business sustainability—by benchmarking cost levels, discerning the reasons behind the rise in cost, and proposing efficient cost management procedures.
-
Research is the key to success, and we have made it a priority to stay ahead of the game. This helps us identify the right CDMO for our customers
FMC also identifies growth opportunities within the thriving CDMO sector by pinpointing achievable growth prospects, sources of growth, and the necessary steps to capitalise on opportunities. This may involve strategic investments in relevant technologies, expansion into new geographic regions, or optimising existing resources to achieve their full potential. The firm also evaluates and enhances the business development improvement opportunities of CDMOs. To drive growth effectively, CDMOs require a strategic business development approach. FMC assesses existing practices, further scrutinising processes, customer-centricity, RFQ management, and lead identification methodologies. Comparing these practices to industry best standards and identifying enhancement opportunities ensures investors are well-informed about the state of business development within their target CDMO.
Focused, Mindful, and Committed
FMC not only represents the firm’s name but encapsulates the work culture it champions—one that is focused, mindful, and committed. Under the visionary leadership of Kansos and Ntortas, who bring in extensive industry-specific expertise, the firm has experienced a significant increase in its client base, a testament to the confidence clients place in its capabilities.
Continuing this trajectory, FMC will stand as a trusted guide, offering its clients invaluable support and strategic clarity and ensuring they thrive in an industry that demands precision and expertise.
